Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 64, Issue 9, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00245-20
Keywords
herpes simplex virus 2; BX795; genital infection; protein kinase R; antiviral drug; antiviral agents; genital disease; herpes simplex virus; tolerance
Categories
Funding
- NIH/NIAID [R01AI139768]
Ask authors/readers for more resources
Herpes simplex virus type 2 (HSV-2) causes recurrent lesions in the anogenital area that may be transmitted through sexual encounters. Nucleoside analogs, such as acyclovir (ACV), are currently prescribed clinically to curb this infection. However, in some cases, reduced efficacy has been observed due to the emergence of resistance against these drugs. In our previous study, we reported the discovery of a novel anti-HSV-1 small molecule, BX795, which was originally used as an inhibitor of TANK-binding kinase 1 (TBK1). In this study, we report the antiviral efficacy of BX795 on HSV-2 infection in vaginal epithelial cells in vitro at 10 mu M and in vivo at 50 mu M. Additionally, through biochemical assays in vitro and histopathology in vivo, we show the tolerability of BX795 in vaginal epithelial cells at concentrations as high as 80 mu M. Our investigations also revealed that the mechanism of action of BX795 anti-viral activity stems from the reduction of viral protein translation via inhibition of protein kinase B phosphorylation. Finally, using a murine model of vaginal infection, we show that topical therapy using 50 mu M BX795 is well tolerated and efficacious in controlling HSV-2 replication.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available